D. Roşu

Transiently achieved very low low-density lipoprotein cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial

Pedro F. Campos, Luciano Lopes de Sousa, Howard D. Rubenstein, 2023, European heart journal.

Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation

H. Huikuri, H. Suryapranata, A. Bagai, 2024, European heart journal. Cardiovascular pharmacotherapy.